Dr. Michael Edward Ivan, MD

Dr. Ivan practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Ivan's NPI, 1669700365, was assigned on November 18, 2009. Dr. Ivan graduated from Rutgers New Jersey Medical School in 2008. Dr. Ivan holds Florida license ME124651.

Dr. Ivan's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Ivan's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Ivan is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Ivan to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ivan practices, 3 sites in all. Vendor and product names are available with a free account.

Neurological surgery is Dr. Ivan's primary specialty in the NPI Registry, under taxonomy code 207T00000X. Dr. Ivan is board certified in neurological surgery by the American Board of Neurological Surgery. Dmand AI has Dr. Ivan's licenses on file in 2 states: Florida and California.

Dmand AI lists craniotomy and neck pain and spine problems among the conditions Dr. Ivan treats.

CMS data shows 144 Medicare services from Dr. Ivan across 4 procedure codes in 2024, for 142 Medicare patients. Medicare paid $13,313 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 142 Medicare patients who saw Dr. Ivan in 2024. The largest group is 65 to 74, with 62 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 22% are also on Medicaid. Their average risk score is 1.47, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ivan's median patient age at 67, with 62% women.

In 2024, Dr. Ivan wrote 82 Medicare Part D claims for 34 patients. 98% of them were for generic drugs. CMS names the drug for 20 of them, across 1 drug with 11 or more claims each, at $400 in total drug cost. In 2023, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Ivan for performance year 2024, reported as part of a group. Dr. Ivan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ivan as offering telehealth.

Dmand AI links 264 papers to Dr. Ivan, published from 2010 to 2025. 2024 was the busiest year, with 28. The most frequent topics are Brain Neoplasms, Neurosurgical Procedures and Glioblastoma. Dr. Ivan has published most often in World Neurosurg. Dr. Ivan's most frequent co-authors are Ricardo Jorge Komotar, MD, Ashish Harish Shah, MD and Evan Luther, MD.

Dmand AI links Dr. Ivan to 7 clinical trials, 2 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Bile Duct Neoplasms, Brain Neoplasms and Craniopharyngioma. Tocagen Inc. sponsors the most, 2.

CMS Open Payments shows 274 general payments to Dr. Ivan from 16 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 45% of the total. Medtronic, Inc. paid the most, $137,908.

Dmand AI lists 26 awards for Dr. Ivan, most recently CNS Leadership Institute - Selected Participant in 2019.

Dr. Ivan graduated from Rutgers New Jersey Medical School in 2008. Dr. Ivan is a member of AANS and CNS.

Dr. Ivan is in network with 11 carriers, including Aetna, Elevance and United Healthcare. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.